RegeneRx Biopharmaceuticals, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, CohnReznick LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0014 USD | -97.32% | 0.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.11K | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-14.82% | 15.36B | |
-8.82% | 11.95B | |
-16.29% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- RGRX Stock
- News RegeneRx Biopharmaceuticals, Inc.
- RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt